Accumulating research suggests that heparanase may be a universal tumor-associated antigen (TAA) 
Introduction
Advanced malignant tumors are often characterized by invasion and metastasis (1) . The prognosis of patients with tumor metastasis is very poor, and metastasis continues to be a major cause of mortality in patients with tumors. Once metastasis occurs, patients often lose the option of surgical treatment and must rely on chemotherapy and radiotherapy instead. Due to the severe adverse effects of these therapies, patients often do not tolerate these treatments well. Therefore, immunotherapies based on dendritic cells (DCs), which have the advantages of strong immunogenicity and limited adverse effects, have become a topic of interest in the search for treatments for malignant tumors (2) (3) (4) (5) . DCs loaded with tumor-associated antigens (TAAs) initiate antigen-specific immune responses and are usually used to induce anti-tumor responses (5, 6) . However, all TAAs currently identified have tissue specificity; for example, MART-1 is only directed against melanoma, and PSA is only found in association with prostatic carcinoma, etc. Therefore, immunotherapy targeting these TAAs is limited to the corresponding tumor, which leads to narrow therapeutic windows. Thus, it is important to search for a universal tumor-specific antigen (7) .
Heparanase (Hpa) is a unique endogenous endoglycosidase that cleaves heparan sulfate proteoglycans (HSPG), the main proteoglycan component of the ECM (8) .
Heparanase expression has been reported to be correlated with a poor prognosis for cancer patients (9) (10) (11) in almost all advanced malignant tumors. Furthermore, inhibition of heparanase significantly reduced invasion and metastasis of tumor cells (12) (13) (14) (15) , and several potent heparanase inhibitors have shown promising efficacy at the pre-clinical stage. One of representative heparanase inhibitors, PI-88, has been evaluated in a multicenter phase II or III clinical trial (1, 7) , but due to the multiple biologic activities of heparanase inhibitors, the mechanism of their anti-tumor activity and their relation with heparanase inhibition are not clear, therefore, the application of heparanase inhibitors in the clinic may require further studies (16) (8, (17) (18) (19) (20) (21) (22) . In fact, several T cell epitopes of heparanase have been identified (18) (19) (20) (21) .
Although promising results of tumor immunotherapy based on peptide vaccines have been demonstrated from animal studies, limited objective clinical responses have been observed in cancer patients (23, 24) . An explanation may be related to the immunogenicity of the peptide vaccines. Synthetic peptide vaccines offer advantages for therapeutic use; they are easy to produce even at clinical grade, free from pathogen contamination, chemically stable and they have minimal oncogenic potential.
Unfortunately, due to their small molecular weight, weak immunogenicity, and rapid degradation, peptide vaccines cannot elicit an ideal immune response in the body.
Therefore, their clinical application has been limited. To solve this problem, the method of cross-linking epitopes to carrier proteins was often used to increase the immunogenicity of peptide vaccines. However, because carrier proteins are foreign antigens with high molecular weight, the induced antibody response is usually directly against carrier proteins rather than against the target polypeptides.
The Tam laboratory proposed the design of multiple antigen peptides (MAP) in 1988(25) (in which lysine with small molecular weight and weak immunogenicity was considered as the core matrix). Several strips (generally four or eight) of epitope monomer are coupled together to form a branch-like structure. This design strengthens the specificity of the peptide chain structure of the epitope and, at the same time, increases the molecular weight of the epitope peptide. The MAP structure simulates the conformation of the target protein and induces strong immune response without the use of a carrier protein. The attribution of increased in vivo stability of epitope peptides allows peptide molecules to be used for the specific targeting of pathological markers and pathogens (26) . It has great prospects for application in vaccine research and development, as well as in tumor immunotherapy (27) (28) (29) . The design principle of MAP vaccines can be used for B-cell and T cell epitopes (26, 27) .
Recently, Yang et al synthesized a MAP vaccine with B cell epitopes from heparanase in vitro using MAP vaccine theory (30) . In vitro studies showed that this MAP vaccine induced heparanase-specific antibodies, produced heparanase-specific 
Materials and Methods

Mice and cell lines
Eight-week-old female C57BL/6(H-2K b ) mice were purchased from the Third Cells were kept at 37 °C at 5% CO 2 , medium was refreshed every two days. (31) . The purity of the peptides was confirmed by analytical high performance liquid chromatography (HPLC), and their identity was confirmed by mass spectrographic analysis.
Dendritic cell polypeptide pulsing
We generated dendritic cells from bone marrow of C57BL/6 mice. The method of generate DCs from mouse bone marrow were performed as our previously described (19) . Murine bone marrow-derived dendritic cells were cultured in 1 ml of RPMI-1640 containing 10% FCS, 50 ȝmol/L 2-mercaptoethanol, 2 mmol/L L-glutamine, 100 U/ml penicillin, 100 ȝg/ml streptomycin. The concentration of peptide pulsing is 30 ȝmol/L. The different MAP peptides and their corresponding linear peptide and DCs were incubated at 37 °C for 3 h, respectively. Then DCs were washed by normal saline for twice and used for further experiments.
Induction of memory T cells in vivo
C57BL/6 mice were immunized by subcutaneously (s.c.) injection of 1 10 6 of the above peptide-pulsed dendritic cells for three times, once a week. As a control, mice were vaccinated with the same procedure, but using negative peptide-pulsed dendritic cells as described previously (19, 21) .
Prepare Hpa-specific effector cells
Mice were sacrificed seven days after the third vaccination, and their spleens were removed. Ficoll-purified lymphocytes were incubated (4 10 5 /ml) with different peptides (30 ȝmol/L) in 6-well plates in RPMI-1640 containing IL-2 (50 U/ml). After five days of incubation, the lymphocytes from C57BL/6 spleen were collected for standard 4-hour 51 Cr-release assay (19, 21) .
Cytotoxicity assays
Standard 4-hour 51 Cr-release assays were employed to evaluate the ability of 
Enzyme-linked Immunospot (ELISPOT) Assay for IFN-Ȗ
IFN-Ȗ-producing cells in effectors were tested by ELISPOT assay as described previoulsy (18, 19) . Briefly, C57BL/6 mice were immunized by subcutaneously (s.c.)
injection of 1 10 6 of MAP4-mHpa398-, MAP4-mHpa519-, mHpa398-, and mHpa519-pulsed dendritic cells for three times, once a week. One week after the last immunization, the spleen cells from mice were used as CTLs. Ficoll-purified spleen CD8+ T lymphocyte (CD8+ T-cell isolation kit, Miltenyi Biotec) were isolated and cultured in antibody-coated 96-well nitrocellulose plates at a final concentration of 
Immunoprotection and immunotherapy by MAP vaccines derived from mHpa(19)
For protective vaccination, 30 eight-week-old C57BL/6 mice were divided into six 
Survival rates of tumor-bearing mice after injection of therapeutic vaccine(19)
Thirty mice were randomly divided into 6 groups. B16 cells (2 × 10 5 ) were injected subcutaneously in the back flank. After 7 days, when palpable tumors (about 1 mm in diameter) had developed, MAP4-mHpa519-, MAP4-mHpa398-, mHpa519-, or mHpa398-pulsed dendritic cells were injected s.c. 3 times at 7-day intervals. 
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All experiments were performed in triplicate; the results are presented as mean± SD.
Statistical analyses were performed using the one way analysis of variance with post Tukey test. P < 0.05 was considered statistically significant. All statistical analyses were carried out using SPSS 11.5 software. Survival analysis was performed using a Kaplan-Meier analysis and log-rank test by Prism 5.0 software (GraphPad). Lewis lung cancer cells, and P815 mastocytoma cells ( Fig. 2A and 2B) . However, H-2K b expressing on the surface of target cells was detected on B16, EL-4 and Lewis lung cancer cells, but not on P815 cells (Fig. 2C) .
Results
Synthesis
Identification of mouse bone marrow-derived dendritic cells
Mature dendritic cells generated from bone marrow-derived cells using GM-CSF, 
IL-4, and TNF-Į. The dendritic cells were harvested and the phenotype of DCs were analyzed by flow cytometry. The results showed mature dendritic cells we generated expressing high levels of CD86 (82.5%), CD11c (73.2%), and MHC-II (80.1%), H-2K b (84.5%) (Fig. 2D) .
Synthetic peptide induction of CTLs specific for murine heparanase
To detect whether mHpa MAP vaccines could elicit stronger heparanase-specific CTL responses against various tumor cells than corresponding linear peptides in vivo, mDCs were pulsed with MAPs, and their corresponding linear peptides or a negative control peptide. Next, C57BL/6 mice were vaccinated s.c. three times at 7-day intervals with the peptide-pulsed dendritic cells as our previously described (20) . At the highest E/T ratio, 80:1, the lysis rate was greater than 20%. Whereas, the effectors could not lyse Hpa-positive and H-2K b -negative cell (P815 cells), even the E/T at 80:1. Effectors generated from the negative peptide failed to lyse target cells (Fig 3A, 3B, 3C and 3D ). Taken together, these results indicate that MAP vaccines are capable of eliciting a more powerful heparanase-specific CTL response, compared with that elicited by vaccination with their corresponding linear peptides.
Killing effect of murine heparanase-specific CTLs on autologous lymphocytes and dendritic cells
It has reported that in normal tissue, very low level expression of heparanase could be (Fig. 3E and 3F ).
ELISPOT assay for IFN-Ȗ producing cells
IFN-Ȗ-producing cells induced by vaccination were quantitated by ELISPOT assay.
As shown in Fig. 4 , vaccination with MAP4-mHpa398-, MAP4-mHpa519-, mHpa398-, and mHpa519-pulsed dendritic cells generated peptide-specific T cell responses; MAP vaccinations induced increased frequencies of IFN-Ȗ-producing T cells, compared with vaccination with control peptides (p<0.05). Also, mice vaccinated with MAP4-mHpa398 and MAP4-mHpa519 induced increased numbers of IFN-γ positive cells than mice vaccinated with their corresponding linear peptides mHpa398 and mHpa519 (p<0.05). We also found that the number of IFN-Ȗ-positive cells was significantly reduced after CD4+ T cells were depleted (p<0.05) (Fig. 4A and 4B). These results suggest that the generation of IFN-Ȗ-producing cells depend on the help of CD4+ T cells. Furthermore, tumor size was also significantly smaller in the MAP4-mHpa398 and MAP-mHpa519 therapeutic groups than it was in the mHpa519 and mHpa398 groups (Fig. 5A) (p<0.05) .
Induction of immunoprotection and immunotherapy in mice
To investigate the immunoprotection potential of vaccination with MAP4-mHpa398-, MAP4-mHpa519-, mHpa398-and mHpa519-pulsed dendritic cells in vivo, we vaccinated mice with peptide-pulsed dendritic cells three times at weekly intervals. Next, B16 melanoma cells were inoculated to C57BL/6 mice by s.c. cells, mice were sacrificed and the tumors were removed. Tumor size was measured using a caliper ruler. In these experiments, all mice vaccinated with MAP4-mHpa398-, MAP4-mHpa519-, mHpa398-, and mHpa519-pulsed dendritic cells were protected from tumor growth. Tumor size in MAP4-mHpa398, MAP4-mHpa519, mHpa398, and mHpa519 groups was significantly smaller than tumor size in the control groups (p<0.05). Furthermore, tumor size in MAP4-mHpa398 and MAP4-mHpa519 protective groups was also smaller, compared with tumor size in the mHpa519 and mHpa398 groups (Fig. 5B) . Taken together, these data indicate that murine heparanase-derived MAPs offer a strong possibility not only to immunize against tumors but also to treat tumor-bearing hosts successfully. The survival of mice bearing tumors was observed for 90 days after the development of palpable tumors. Mice in the negative peptide (NP) and PBS control groups started dying 25 days after tumor cell inoculation; all mice in the control groups had died by day 37. Mice that received therapeutic vaccinations with mHpa398-or mHpa519-pulsed dendritic cells began dying at day 48 post-inoculation; however, multiple mice from this group survived until the end of the 90-day observation period, resulting in a 40% survival rate. Mice in the MAP4-mHpa398 treatment group began dying at day 85 post-inoculation and exhibited an 80% survival rate at the end of the experiment. All mice treated with MAP4-mHpa519-pulsed dendritic cells survived until the end of the observation period, resulting in a survival rate of 100% (Fig. 6 ). 
Survival rates after therapeutic vaccinations
Discussion
immunogenicity. MAPs, which are based on a small immunologically inert core molecule with radial branching lysine residues that allow for a number of peptide antigens to be anchored, offer an attractive alternative to conventional linear peptide approaches (25, 37) . Thus, MAP structure results in a large macromolecule with a unique three-dimensional configuration that has a high molar ratio of peptide antigen to core molecule and that does not require a carrier protein for elicitation of immune responses. Since invention of these molecules, most MAPs have been used as antigens in serodiagnostic tests and in vaccine discovery (3, 5, 6) .
Our previous study found that three four-branched MAP vaccines based on HLA-A2-restricted CTL epitopes of human heparanase elicited stronger immune response against various tumor cell lines than did corresponding linear peptide vaccines both in vitro and ex vivo (38) . Because the mechanisms of antigenic uptake, presentation, and immune response induction in vivo are extremely complex, whether these MAP vaccines could generate much stronger immune response in vivo remained unknown.
In the present study, we generated two four-branched MAP vaccines based on previously identified H-2K b -restricted murine heparanase CTL epitopes (19) . 
